Search clinical trials for: Ribocyclib, fulvestrant, triptorelin

Total 765 results

Korea University Guro Hospital

Recruiting

Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Metastatic Breast Cancer

Korea, Republic of
Hospital de Niños R. Gutierrez de Buenos Aires

Completed

Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls

Central Precocious Puberty | Sexual Precocity

Argentina
Saint Petersburg State Budgetary Healthcare Institution...

Active, not recruiting

The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

The Neoadjuvant Therapy

Russian Federation
Universitaire Ziekenhuizen KU Leuven
Ipsen

Recruiting

Long-term Better Than Short-term ADT With Salvage RT (LOBSTER)

Prostate Cancer

Belgium
Institut fuer Frauengesundheit
Novartis Pharmaceuticals; AGO Breast Study Group e.V.

Recruiting

Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients (CAPTOR-BC)

Breast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast Cancer

Germany
Fox Chase Cancer Center

Terminated

Impact of Ribociclib on Head and Neck Squamous Cell Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
Novartis Pharmaceuticals

Recruiting

Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France (RosaLEE)

Breast Cancer

France
Novartis Pharmaceuticals

Temporarily not available

Managed Access Programs for LEE011, Ribociclib

Breast Cancer
Novartis Pharmaceuticals

Completed

Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011

Normal Hepatic Function | Impaired Hepatic Function

United States
Hadassah Medical Organization

Unknown

A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma

Soft Tissue Sarcoma | Liposarcoma

Israel
Nanjing University

Unknown

Comparative Study of Long-acting and Short Acting Triptorelin in PCOS Patients Who Underwent IVF/ICSI

Polycystic Ovary Syndrome | In Vitro Fertilization

China
Aristotle University Of Thessaloniki
Eugonia IVF Unit, Athens, Greece

Unknown

Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients (ATD)

Subfertility

Greece
Sir Mortimer B. Davis - Jewish General Hospital

Recruiting

Management of Castration-Resistant Prostate Cancer With Oligometastases (PCS IX)

Castration-resistant Prostate Cancer Patients With Oligometastases

Canada
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. (MONALEESA-3)

Advanced Breast Cancer

Belgium, Italy, Czechia, Hungary, Canada, Netherlands, Germany, Singapore, Australia, Denmark, Poland, Switzerland, Korea, Republic of, Spain, Thailand, Lebanon, Austria, Bulgaria, Russian Federation, Norway, Jordan, United States, ... and more
UNICANCER
Novartis; Breast Cancer Research Foundation

Recruiting

Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib (SAFIR 03)

Breast Cancer Stage IV

France
Blueprint Medicines Corporation

Recruiting

(VELA) Study of BLU-222 in Advanced Solid Tumors

Gastric Cancer | Ovarian Cancer | Carcinosarcoma | Advanced Solid Tumors | Endometrial Cancer | Esophageal Adenocarcinoma | HER2-negative Breast Cancer | CCNE1 Amplification | HR+ Breast Cancer

United States, Italy, United Kingdom
Instituto Valenciano de Infertilidad, IVI VALENCIA

Completed

GnRH Agonist and Intrauterine Insemination

Intrauterine Insemination

Spain
Novartis Pharmaceuticals

Recruiting

A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer

Breast Cancer

Jordan
Nader Sanai
Novartis; Barrow Neurological Institute; Ivy Brain Tumor Center

Active, not recruiting

Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients

Glioblastoma Multiforme | Meningioma

United States
Assaf-Harofeh Medical Center

Unknown

A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma

Soft-Tissue Sarcoma | Liposarcomas, Dedifferentiated | Liposarcoma - Well Differentiated | Liposarcoma; Mixed Type

Israel
Children's Hospital Medical Center, Cincinnati
Novartis

Terminated

A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy

High Grade Glioma | Diffuse Intrinsic Pontine Glioma | Bithalamic High Grade Glioma

United States
Relay Therapeutics, Inc.

Recruiting

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Solid Tumor, Adult | HER2-negative Breast Cancer | Unresectable Solid Tumor | PIK3CA Mutation

United States, Spain, France, Italy
Genor Biopharma Co., Ltd.

Recruiting

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Locally Advanced or Metastatic Breast Cancer

China
Novartis Pharmaceuticals

Recruiting

A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia (ValerEE)

HR+HER2- Advanced Breast Cancer

Russian Federation
Tvardi Therapeutics, Incorporated

Completed

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Breast Cancer

United States
Ipsen

Completed

Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis

Endometriosis

China
Cairo University

Completed

Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI

Invitro Fertilization

Egypt
Chenshiling
National Natural Science Foundation of China; Comprehensive Strategic Cooperation... and other collaborators

Unknown

Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome

Infertility and at High Risk of OHSS

China
Array BioPharma

Terminated

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

Locally Advanced Metastatic BRAF Mutant Melanoma

Australia, Canada, Netherlands, United States
SOLTI Breast Cancer Research Group
Novartis; UNICANCER

Recruiting

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer (RIBOLARIS)

Breast Cancer Stage II

Spain, France, Portugal
West German Study Group
Novartis; Genomic Health®, Inc.

Recruiting

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC (ADAPTcycle)

Breast Cancer Female

Germany
Novartis Pharmaceuticals

Completed

Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer

Breast Cancer

Brazil
SOLTI Breast Cancer Research Group
Novartis; Alliance Foundation Trials, LLC.

Recruiting

Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype (HARMONIA)

Metastatic Breast Cancer

United States, Spain, Portugal
Royal Marsden NHS Foundation Trust
Pfizer; Hoffmann-La Roche

Recruiting

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression (FAIM)

Advanced Breast Cancer | Metastatic Breast Cancer | ER+ Breast Cancer

United Kingdom
IVI Madrid

Completed

Endometrial Receptivity After GnRH Agonist Triggering (ERAMAD)

Ovarian Hyperstimulation Syndrome

Spain
Masaryk University
Ministry of Health, Czech Republic

Completed

Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients (OVARONKO)

Hodgkin Disease | Hodgkin Lymphoma

Czech Republic
Universitair Ziekenhuis Brussel
Universitaire Ziekenhuizen KU Leuven

Recruiting

DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation (Depo-Trigger)

Breast Cancer Female

Belgium
University of Michigan Rogel Cancer Center

Recruiting

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer

Breast Cancer

United States
Swiss Group for Clinical Cancer Research
The Belgian Society of Medical Oncology

Terminated

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

Breast Cancer

Switzerland, Belgium, Austria
Bart CJM Fauser

Terminated

A Study of the Effects of a Novel Ovarian Stimulation Regimen on Embryo Aneuploidy Rates in In Vitro Fertilization (IVF)

In Vitro Fertilization

Netherlands
AstraZeneca

Recruiting

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) (CAPItello-292)

Locally Advanced (Inoperable) or Metastatic Breast Cancer

Spain, Denmark, United States, Korea, Republic of, Germany, Belgium, Vietnam, United Kingdom, France, Japan, Brazil, Canada, China, India, Malaysia, Taiwan, Thailand, Australia, Turkey, Argentina, Poland, Sweden, Italy
Fondazione Sandro Pitigliani
Novartis

Active, not recruiting

FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer (FACILE)

Breast Cancer

Italy
Novartis Pharmaceuticals
Translational Research in Oncology

Active, not recruiting

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE)

Early Breast Cancer

United States, Belgium, Canada, Italy, United Kingdom, Hungary, Taiwan, Australia, Germany, Spain, Austria, Russian Federation, Korea, Republic of, China, France, Brazil, Ireland, Argentina, Romania, Poland
Dana-Farber Cancer Institute
Novartis

Completed

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

Breast Cancer

United States
The First Affiliated Hospital with Nanjing Medical...
Zhejiang Cancer Hospital

Recruiting

Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

Advanced Breast Cancer

China
Ontario Clinical Oncology Group (OCOG)
AstraZeneca

Completed

Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer (ZAMBONEY)

Metastatic Breast Cancer

Canada
Kaunas University of Medicine

Unknown

Investigation of Early Hormonotherapy Efficacy of Prostate Cancer

Prostate Cancer

Lithuania
Centre Antoine Lacassagne

Recruiting

Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS) (CALHYS)

HER2 Negative Breast Cancer Not Immediately Operated

France
Parc de Salut Mar

Completed

Generation of Biological Samples Positive to Triptorelin for Anti-doping Control (TRIPTO)

Healthy Volunteers

Spain
Tampere University Hospital

Completed

Luteal Phase Support in Insemination Cycles

Infertility, Female

Finland

Search clinical trials for: Ribocyclib, fulvestrant, triptorelin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations